- Trials with a EudraCT protocol (506)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
506 result(s) found for: Inflammatory bowel disease.
Displaying page 26 of 26.
EudraCT Number: 2017-004230-28 | Sponsor Protocol Number: 1368-0005 | Start Date*: 2018-02-27 | |||||||||||
Sponsor Name:Boehringer Ingelheim RCV GmbH & Co KG | |||||||||||||
Full Title: A Phase II/III Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of BI 655130 (SPESOLIMAB) Induction Therapy in patients with moderate-to-severely ... | |||||||||||||
Medical condition: Moderate-to-severely active ulcerative colitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) BE (Prematurely Ended) DE (Completed) GB (Completed) ES (Prematurely Ended) NL (Prematurely Ended) DK (Prematurely Ended) GR (Prematurely Ended) HU (Completed) CZ (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-005032-35 | Sponsor Protocol Number: ATL2502/020/CL | Start Date*: 2005-10-11 |
Sponsor Name:Alizyme Therapeutics Limited | ||
Full Title: A Multicentre, Randomised, Double-Blind, Double-Dummy, Active Comparator Controlled, Parallel Group Study of COLAL PRED® in the Treatment of Moderate Acute Ulcerative Colitis. | ||
Medical condition: Moderate acute ulcerative colitis. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) SE (Completed) CZ (Completed) HU (Completed) DK (Completed) ES (Ongoing) BE (Completed) IT (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2017-003703-22 | Sponsor Protocol Number: P2-IMU-838-UC | Start Date*: 2018-05-03 | |||||||||||
Sponsor Name:Immunic AG | |||||||||||||
Full Title: A phase 2, multicenter, randomized, double-blind, placebo controlled, dose-finding study to evaluate the efficacy and safety of IMU 838 for induction and maintenance therapy in moderate-to-severe u... | |||||||||||||
Medical condition: Ulcerative Colitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) ES (Prematurely Ended) NL (Completed) PL (Completed) PT (Completed) HR (Completed) BG (Completed) RO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-004300-34 | Sponsor Protocol Number: MLN0002-3024 | Start Date*: 2021-06-25 | |||||||||||
Sponsor Name:Takeda Development Center Americas, Inc. | |||||||||||||
Full Title: A Randomized, Double-Blind, Phase 3 Study to Evaluate the Efficacy and Safety of Vedolizumab Intravenous as Maintenance Therapy in Pediatric Subjects with Moderately to Severely Active Ulcerative C... | |||||||||||||
Medical condition: Moderately to severely active Ulcerative Colitis (UC) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: LT (Completed) CZ (Prematurely Ended) SK (Prematurely Ended) HU (Trial now transitioned) GR (Trial now transitioned) IT (Trial now transitioned) ES (Prematurely Ended) HR (Trial now transitioned) BE (Trial now transitioned) Outside EU/EEA PL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-001087-30 | Sponsor Protocol Number: CT-P13_3.8 | Start Date*: 2019-07-25 | |||||||||||
Sponsor Name:Celltrion, Inc | |||||||||||||
Full Title: A Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study to Evaluate the Efficacy and Safety of the Subcutaneous Injection of CT-P13 (CT-P13 SC) as Maintenance Therapy in Patients With Moderat... | |||||||||||||
Medical condition: Moderately to Severely Active Crohn’s Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LV (Completed) CZ (Completed) SK (Completed) FR (Completed) PL (Completed) DE (Completed) GR (Completed) HU (Completed) ES (Completed) AT (Completed) BG (Completed) HR (Completed) IT (Completed) RO (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-001430-33 | Sponsor Protocol Number: GS-US-365-4237 | Start Date*: 2020-05-15 |
Sponsor Name:Gilead Sciences, Inc. | ||
Full Title: A Phase 2, Blinded, Randomized, Placebo-Controlled Study Evaluating the Efficacy and Safety of GS-4875 in Subjects with Moderately to Severely Active Ulcerative Colitis | ||
Medical condition: | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) FR (Completed) GB (GB - no longer in EU/EEA) DE (Completed) PL (Completed) BE (Completed) IT (Completed) | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
